Autoimmunity

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer

Retrieved on: 
Monday, March 18, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Fairfield University, Quell, Autoimmunity, Synthetic biology, Patient, GRO, Doctor of Philosophy, MD, Biology, Bayer, Therapy, Drug development, Multimedia, FDA, Animal, Autoimmune disease, Pharmaceutical industry

Dr. Lodie most recently worked as Chief Scientific Officer at Quell Therapeutics where she led the company’s scientific strategy and worked to build their immune-driven pipeline.

Key Points: 
  • Dr. Lodie most recently worked as Chief Scientific Officer at Quell Therapeutics where she led the company’s scientific strategy and worked to build their immune-driven pipeline.
  • “We are delighted to add Tracey to our executive team.
  • Her world-class experience in immunology, clinical translation, development, and commercialization will be instrumental as we advance our programs into the clinic,” said Daniel J. Mandell, PhD, Chief Executive Officer of GRO Biosciences.
  • Dr. Lodie’s addition to the executive team brings critical management expertise to support the continued evolution of GRO Biosciences into a clinical-stage organization.”

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 18, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Research program, Administration, Congress, Development, WT, Lupus, Patient, Immunoglobulin A, Glomerular filtration rate, SLE, Inflammation, MD, UPCR, Neonatal Fc receptor, American College, Investment, Clinical trial, Society, EGFR, Nephrology, BAFF, Proteinuria, Immunoglobulin G, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
  • “2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-class profile for povetacicept, our next-generation dual BAFF/APRIL inhibitor.
  • In addition, povetacicept was well tolerated during subcutaneous administration, with no instances of IgG
  • Net Loss: Net loss for the year ended December 31, 2023, was $32.2 million compared to $57.8 million for the same period in 2022.

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: Pioneering New Drug Class with Versatile Therapeutic Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Other Health, Health, Science, Pharmaceutical, Research, Multiple myeloma, Toxicity, Antigen, Haemophilia A, Cell, Autoimmunity, Patent, Carcinoma, Risk, Inflammation, Haemophilia, Malignancy, Monoclonal antibody, Neoplasm, Tissue, Patient, Tumor microenvironment, Antibody, Cancer, Bladder cancer, Leukemia, Diabetic retinopathy, Indication, Cytokine, Immune system, Therapy, Infection, Priority, Physician, Engineering, Escape Room, Acute lymphoblastic leukemia, Vaccine

The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types.
  • Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class.
  • Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:
    Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
    Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
    Clinical & Commercial Insight on Approved Bispecific Antibodies: 12 Antibodies
    Global Bispecific Antibodies Clinical Trials by Company, Indication & Phase: > 800 Antibodies
    FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Retrieved on: 
Wednesday, April 3, 2024
Research, University, IPO, Credit Suisse, Inflammation, MBA, Union College, Therapy, Economics, Autoimmunity

WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer.

Key Points: 
  • WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer.
  • "Lee has been part of the Q32 Bio team over the past five months as our interim Chief Financial Officer and an invaluable member of the team driving the execution and closing of our recent transactions.
  • Prior to joining Q32 Bio, Mr. Kalowski served as President and Chief Financial Officer of Bicycle Therapeutics where he led strategic finance and operations and oversaw the company's transition to a public clinical-stage biotech company.
  • Prior to Bicycle, Mr. Kalowski was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company's IPO in 2014.

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

Retrieved on: 
Wednesday, April 3, 2024
Rheumatoid arthritis, Autoimmunity, Lupus, Risk, Rheumatism, Patient, PSS, SLE, Diabetic nephropathy, Myasthenia gravis, IND, Mouth, Investigational New Drug, Cytokine, B-cell activating factor, Iga, FDA, FTD

The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.

Key Points: 
  • The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.
  • Telitacicept prevents abnormal differentiation and maturation of B-cells through a two-pronged approach, thereby treating various autoimmune diseases mediated by B-cells.
  • In December 2023, Telitacicept was granted Investigational New Drug (IND) by the FDA for the treatment of active pSS in adults.
  • Dr. Jianmin Fang, CEO of RemeGen, commented, "As the first fusion protein drug of its kind independently developed by RemeGen, we are delighted the FDA has recognized Telitacicept for fast track designation.

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

Retrieved on: 
Tuesday, April 2, 2024
Cell engineering, Immunotherapy, Partnership, Library, Research, DNA, Gene, Acquisition, Society, Wisconsin Alumni Research Foundation, Therapy, Modulus, Safety, Poster, SITC, Cell, WARF, Autoimmunity, Annual general meeting, Vaccine

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.

Key Points: 
  • Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
  • In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors.
  • Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date.
  • Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings.

THE DERMATOLOGY FOUNDATION AND SKIN OF COLOR SOCIETY BESTOW THE FIRST-EVER SANOFI AND REGENERON DIVERSITY, EQUITY, AND INCLUSION MID-CAREER AWARD ON DONALD A. GLASS II, MD, PhD, FAAD

Retrieved on: 
Tuesday, March 19, 2024
SOCS, Autoimmunity, University, Glass, Regeneron Pharmaceuticals, Associate, Health equity, Genetics, Patient, DF, Research, Diversity, American Academy, Doctor of Philosophy, MBA, Skin, University of Massachusetts, MPH, Comorbidity, FAAD, Bangladesh Technical Education Board, DEI, Vitiligo, Medicine, Pharmaceutical industry

CHICAGO, March 19, 2024 /PRNewswire/ -- The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Donald A. Glass II, MD, PhD, FAAD, is the 2024 recipient of the first-ever Sanofi and Regeneron Diversity, Equity, and Inclusion (DEI) Mid-Career Award, given to support his research into "Genetics, Comorbidities and their Association with Keloids."

Key Points: 
  • A nationally recognized keloids expert, Dr. Glass is an Associate Professor at the University of Texas Southwestern Medical Center in Dallas, Texas.
  • He served as 2021-2022 President of the Skin of Color Society.
  • The Sanofi and Regeneron DEI Mid-Career Award was developed especially for the exceptional mid-career investigator with an established trajectory of excellence in basic, clinical or translational science.
  • Our sincere congratulations to Dr. Glass, the outstanding first award recipient for this highly competitive award—and our sincere gratitude to Sanofi and Regeneron for making the award possible."

Telum Therapeutics appoints Dr. Subhendu Basu as CEO

Retrieved on: 
Tuesday, March 19, 2024
Medical school, Infection, Autoimmunity, APT, Inflammation, University, Research, Head, Doctor of Philosophy, APEX, Gram, Therapy, School

PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.

Key Points: 
  • PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.
  • "I am truly inspired by Telum's cutting-edge science, its dynamic pipeline, and the team's accomplishments thus far," remarked Dr. Basu.
  • "As CEO, I am eager to collaborate with the Telum scientific team and our dedicated investors to spur growth and advance Telum's investigational products into clinical trials for patient benefit."
  • Reflecting on the transition, Dr. Díez-Martínez remarked, "After years of progress and technological breakthroughs at Telum, I warmly welcome Dr. Basu as the new CEO.

Telum Therapeutics appoints Dr. Subhendu Basu as CEO

Retrieved on: 
Tuesday, March 19, 2024
Medical school, Infection, Autoimmunity, APT, Inflammation, University, Research, Head, Doctor of Philosophy, APEX, Gram, Therapy, School

PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.

Key Points: 
  • PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.
  • "I am truly inspired by Telum's cutting-edge science, its dynamic pipeline, and the team's accomplishments thus far," remarked Dr. Basu.
  • "As CEO, I am eager to collaborate with the Telum scientific team and our dedicated investors to spur growth and advance Telum's investigational products into clinical trials for patient benefit."
  • Reflecting on the transition, Dr. Díez-Martínez remarked, "After years of progress and technological breakthroughs at Telum, I warmly welcome Dr. Basu as the new CEO.